OncLive SOSS

Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates - Episode 11

Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC

July 29, 2024

Mark A. Socinski, MD, Helena A. Yu, MD, Zosia Piotrowska, MD, MHS , Julia Rotow, MD, Benjamin Levy, MD

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Treatment Strategies for NSCLC with Non-Actionable Mutations

EP. 2: Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

EP. 3: Exploring the TROPION-Lung04 Study

EP. 4: Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC

EP. 5: Navigating Between ADCs in NSCLC

EP. 6: Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

EP. 7: Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC

EP. 8: MARIPOSA Study Insights

EP. 9: Optimizing Therapy Selection in EGFR Mutant NSCLC

EP. 10: ASCO 2024 Updates: Novel Approaches in NSCLC Therapy

EP. 11: Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC

EP. 12: Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape

EP. 13: Targeting of HER3: Insights from HERTHENA-Lung01

EP. 14: Challenges and Learnings from EVOKE-01

EP. 15: Key ADC Studies at ASCO 2024

EP. 16: Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

EP. 17: Patient Selection and Sequencing of NSCLC ADCs

Please discuss the significance of TROP2 in the development and progression of NSCLC and the role of TROP2-directed ADCs in this treatment setting.

a. How is TROP2 unique as a biomarker in NSCLC?

b. In what ways does it differ from other targetable biomarkers in NSCLC?

c. What is the rationale for TROP2-directed therapies in previously treated

NSCLC?

x